BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
61.46
+1.55 (2.59%)
At close: Aug 6, 2026, 4:00 PM EDT
64.55
+3.09 (5.03%)
After-hours: Aug 6, 2026, 7:45 PM EDT

BioMarin Pharmaceutical Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
3,4073,2212,8542,4192,0961,846
Revenue Growth
11.20%12.87%17.97%15.42%13.53%-0.76%
Gross Profit
2,5932,5042,2741,8871,5931,376
Operating Income
149.26409.48484.21185.77160.97-82.34
Net Income
72.97348.9426.86167.65141.56-64.08
Earnings Per Share
0.371.802.210.870.75-0.35
EPS Growth
-89.02%-18.55%154.02%16.00%--

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
VOXZOGO
964.19926.92735.09469.88169.135.86
VIMIZIM
792.86792.05739.78701.05663.74623.15
NAGLAZYME
507.57485.4479.58420.29443.79380.45
PALYNZIQ
458.83433.31355.05303.92255.03237.47
BRINEURA
195.82186.4169.08161.89154.33128.03
ALDURAZYME
183.38208.51183.89131.25128.42122.77
KUVAN
95.6899.53120.9180.77227.58285.78
ROCTAVIAN
30.2835.6426.073.49--
Royalty and Other
42.0153.4944.4746.6954.0162.78
Revenue (Total)
3,4073,2212,8542,4192,0961,846

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
874.011,5611,1381,0741,2921,014
Total Debt
4,186597.18595.141,0871,0831,079
Net Cash (Debt)
-3,312963.43542.57-13.16208.52-65.2
Net Cash Growth
-77.57%----
Net Cash Per Share
-17.064.882.76-0.071.10-0.36

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
857.09827.99572.84159.26175.9304.54
Capital Expenditures
-118.91-103.04-85.42-96.69-120.96-95.58
Free Cash Flow
738.18724.96487.4262.5754.94208.96
Free Cash Flow Growth
6.23%48.73%679.02%13.88%-73.71%-

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
76.12%77.73%79.67%78.01%76.00%74.52%
Operating Margin
4.38%12.71%16.97%7.68%7.68%-4.46%
Pretax Margin
4.38%14.98%18.98%7.79%7.14%-4.08%
Profit Margin
2.14%10.83%14.96%6.93%6.75%-3.47%
FCF Margin
21.67%22.51%17.08%2.59%2.62%11.32%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
162.1733.0229.74110.83137.99-
Forward PE
10.0112.3717.8638.9839.0085.79
P/FCF Ratio
16.0915.7625.72290.64350.8277.76
PS Ratio
3.493.554.397.529.208.80